SCHEMBL22508271

SCHEMBL22508271

CCn1cnc2c3nc(=O)[nH]c(N)c3ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 2/20 0.38
CCNB1 P14635 2/20 0.38
CCNE1 P24864 2/20 0.38
CDK2 P24941 2/20 0.38
ADORA2A P29274 2/20 0.35
ADORA1 P30542 2/20 0.35
PI4KA P42356 1/20 0.35
PI4K2B Q8TCG2 1/20 0.35
PI4K2A Q9BTU6 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35
ABL1 P00519 1/20 0.35
NTRK1 P04629 1/20 0.35
CSF1R P07333 1/20 0.35
RET P07949 1/20 0.35
IGF1R P08069 1/20 0.35
PDGFRB P09619 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18257688 0.82 DYRK1A (0.38) CDK1CDK2ADORA2AADORA1CHEK1
SCHEMBL22736706 0.80 CYP19A1 (0.39) CDK2PI4KAPI4KBCHEK1AURKA
SCHEMBL18471002 0.80 CHEK1 (0.39) CDK2PI4KAPI4K2BPI4K2API4KB
SCHEMBL19009131 0.79 SMN1; SMN2 (0.39) CDK1CCNB1CCNE1CDK2ADORA2A
SCHEMBL13074136 0.75 CDK1 (0.54) CDK1CCNB1CCNE1CDK2ADORA2A
SCHEMBL16160615 0.70 DHFR (0.41) CDK2CHEK1AURKADAPK3JAK2
SCHEMBL24113799 0.69 CDK1 (0.50) CDK1CCNB1CCNE1CDK2ADORA2A
SCHEMBL23660141 0.68 CHEK1 (0.40) CDK2CHEK1AURKADAPK3JAK2
SCHEMBL21257150 0.67 CHEK1 (0.36) CDK2CHEK1AURKADAPK3JAK2
SCHEMBL16940094 0.67 CHEK1 (0.36) CDK2CHEK1AURKADAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200316210-A1 Cell-Penetrating Peptides For Antisense Delivery SAREPTA THERAPEUTICS, INC. 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200316210-A1 Cell-Penetrating Peptides For Antisense Delivery MYOF, TNNC1, MTPN CDK1 4637/4885CCNB1 3621/4885CCNE1 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.